Antibiotics (MCP-1705) - Global Industry Analysts, Inc.

Research Abstract

This report analyzes the worldwide markets for Antibiotics in US$ Million by the following product segments: Penicillin, Cephalosporins, Macrolides, Quinolones, Carbapenems, and Other Antibiotics (Aminoglycosides, Tetracyclines, Sulfonamides, Mupirocin, Glycopeptides, Synercid, and Oxazolidinones). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 197 companies including many key and niche players such as Abbott Laboratories, Astellas Pharma, Inc., Bayer HealthCare AG, Bristol-Myers Squibb Co., Cubist Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Co., GlaxoSmithKline Plc, Johnson & Johnson, Kyorin Pharmaceutical Co., Ltd., LG Life Sciences Limited, MiddleBrook™ Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Pliva d.d., Roche, Sanofi-Aventis SA, Takeda Pharmaceutical Company, Ltd., and Toyama Chemical Co., Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Code :	MCP-1705
Price :	$4500
Companies :	197

Pages :	850
Date :	October 2010
Market Data Tables :	70

Complimentary Report Insights:

Request a Complimentary Copy of the Study’s Key Findings, Drivers, Trends, Program Sources, and Methodology.

ANTIBIOTICS (Complete Report)

Pages : 850

$4500

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS.......1

$295

Study Reliability and Reporting Limitations.......1

Disclaimers.......2

Data Interpretation & Reporting Level.......2

Quantitative Techniques & Analytics.......3

Product Definitions and Scope of Study.......3

Penicillin.......4

Cephalosporins.......4

Macrolides.......4

Quinolones.......4

Carbapenems.......4

Other Antibiotics.......5

Aminoglycosides.......5

Tetracyclines.......5

Sulfonamides.......5

Mupirocin.......5

Glycopeptides.......5

Synercid.......6

Oxazolidinones.......6

Linezolid.......6

2. INDUSTRY OVERVIEW........7

Antibiotic Resistance and Generic Competition to Impact Long Term Growth........7

New Regulations Guiding Usage of Drugs to Drive Growth........7

Current & Future Analysis........7

$200

3. MARKET DYNAMICS........9

$495

Anti-Bacterials Segment Drives Global Anti- Infectives Market........9

Antibiotic Resistance – A Primary Growth Inhibitor........9

Antibiotic-Resistant Bacteria by Type........9

$100

Patent Expiries Commoditize Antibiotics........10

Patent Expiries of Leading Drugs in the Recent Past, Current, and Future (2000

–2013)........10

Anti-MRSA Antibiotics Find Their Way........10

$100

Table 1: World MRSA Treatments (2007 & 2008) : Percentage Share Breakdown by Leading Antibiotic Drugs -Vancomycin, Zyvox, Cubicin and Tygacil (includes corresponding Graph/Chart)........11

Key Antibiotics in Pipeline........11

$350

4. COMPETITION........12

$1950

Highly Competitive Market........12

Table 2: Leading Players in the Worldwide Antibiotics Market (2008): Percentage Breakdown by Value Sales for Pfizer, Glaxo Smithkline, Sanofi-aventis, Johnson & Johnson, Bayer, Abbott, Wyeth, and Others (includes corresponding Graph/Chart)........12

$350

GlaxoSmithKline – The Undisputed Leader of Penicillin Market........13

Table 3: Worldwide Leading Antibiotics within Penicillin Class (2005 & 2006): Percentage Breakdown by Value for Augmentin, Zosyn/Tazocin, Amoxil, and Others (includes corresponding Graph/Chart)........13

$350

GlaxoSmithKline Leads Cephalosporin Market........14

Table 4: Worldwide Leading Antibiotics within Cephalosporin Class (2005 & 2006): Percentage Breakdown by Value for Rocephin, Ceftin/Zinnat, Flomox, Fortum/Fortaz, Cefzil, Cefzon, Flumarin, and Others (includes corresponding Graph/Chart)........14

$350

Pfizer Dominates Macrolides Market........15

Table 5: Worldwide Leading Antibiotics within Macrolide Class (2005 & 2006): Percentage Breakdown by Value for Zithromax, Klaricid/Biaxin, Ketek, and Others (includes corresponding Graph/Chart)........15

$350

Levaquin/Tavanic – The Most Preferred Quinolone Antibiotic........16

Table 6: Worldwide Leading Antibiotics within Quinolone Class (2005 & 2006): Percentage Breakdown by Value for Levaquin/Tavanic, Avelox, Ciprobay/Ciproxin, Cravid, and Others (includes corresponding Graph/Chart)........16

$350

Merck Rules Carbapenems Market........17

Table 7: Worldwide Leading Antibiotics within Carbapenem Class (2005 & 2006): Percentage Breakdown by Value for Primaxin, Merrem, Invanz, and Others (includes corresponding Graph/Chart)........17

$350

5. PRODUCT OVERVIEW........18

$950

Antibiotics – An Introduction........18

Antibiotic Resistance........18

$100

b–Lactams........19

$100

Classification of Antibiotics........20

Key Milestones in Antibiotic Development........20

Antibiotic Types........20

Penicillin........20

$100

History........21

About the Drug........21

Cephalosporins........21

$100

Treatment........22

Effects of the Drug........22

Macrolides........22

$100

Treatment........23

Quinolones........23

Table 8: Leading Global Ciprofloxacin Brands: (2006-2008) (includes corresponding Graph/Chart)........23

$350

Carbapenems........24

Other Antibiotics........24

Aminoglycosides........24

Treatment........24

Effects of the Drug........24

$100

Tetracyclines........25

Treatment........25

$100

Effects of the Drug........26

Sulfonamides........26

Treatment........26

$100

Effects of the Drug........27

Mupirocin........27

Glycopeptides........27

Synercid........27

$100

Oxazolidinones........28

Linezolid........28

$100

6. RESEARCH FINDINGS........29

New Design for Monitoring Toxin Delivery Activity of Pathogenic Bacteria........29

Cephalosporins Effective when Compared to Penicillin........29

FDA Bans Baytril Antibiotic for Chickens........29

Erythromycin Along with Some Specific Drugs Increase Risk of Sudden Death........29

$100

Rise in Usage of Quinolones for Urinary Tract Infections Leads to Drug

Resistance........30

Polyphor Discovers POL7080 - New Antibiotic Against Gram-Negative Bacteria........30

$100

7. FDA APPROVALS/PATENTS........31

$495

MiddleBrook Obtains NDA Approval for MOXATAG™........31

J&JPRD Seeks FDA Approval for Doripenem Antibiotic........31

J&JPRD Seeks FDA Approval for Investigational Antibiotic, Ceftobiprole........31

GSK Receives Approval for ALTARGO® in Europe........31

$100

APL Receives FDA Approval for Cefpodoxime Proxetil........32

Cubist Receives Approval to Market CUBICIN in Canada........32

Cubist Obtains Approval to Market CUBICIN for Added Indications in EU........32

Cubist Gains Approval for CUBICIN in Taiwan and South Korea........32

Cethromycin Achieves FDA’s Orphan Drug Designation........32

$100

FDA Approves Wockhardt’s Cefotaxime Injection........33

FDA Approves Doxycycline Tablets........33

FDA Approves Clarithromycin........33

FDA Approves Doxycycline Tablets For The US Market........33

Johnson & Johnson Applies Doripenem For FDA Approval........33

FDA Certifies Antibioticos do Brasil’s Plant........33

$100

FDA Certifies ANDA For Cefdinir Capsules........34

US FDA Approves Teva’s Cefprozil Tablets........34

FDA Certifies ANDA for Cephalexin Capsules........34

American Pharmaceutical Partners Receives FDA Approvals for Ceftriaxone for Injection,

USP........34

Advancis’s Keflex Receives FDA Approval........34

Wockhardt Gains Marketing Approval for Cefuroxime axetil in the US........34

$100

Wyeth’s Mylotarq Receives Government’s Approval........35

FDA Approves Generic Version of Zithromax........35

Pfizer Wins FDA Approval for Zmax™........35

$100

Venus Remedies Files Second PCT for New Cephalosporins........36

Falcon Gains US FDA Approval for its Generic Anti-Infective Solution........36

Cadilla Receives FDA Approval to Market Clindamycin........36

$100

8. RECENT INDUSTRY ACTIVITY........37

$395

DSM Opens Eco-friendly Antibiotics Plant ZOR-f, in the Netherlands........37

Daiichi Leverages Ranbaxy’s Network to Market Tavanic in South Africa and

Romania........37

Pfizer Acquires Wyeth........37

Durata Therapeutics Acquires Pfizer’s Vicuron Pharmaceuticals........37

$100

Cubist Completes Acquisition of Calixa Therapeutics........38

AstraZeneca to Acquire Novexel........38

Tianyin and Sichuan Mingxin to Establish an Antibiotic Joint Venture........38

$100

Pfizer and Aurobindo Pharma Ink Agreement for Producing Off Patent Drugs........39

BMP Sunstone to Acquire Majority Stake in Zhangjiakou Shengda........39

Novartis to Take Over Protez Pharmaceuticals........39

$100

3i to Buy Alpharma Unit........40

NCPC to Acquire Stake in DSM’s Antibiotics Division........40

ULL Establishes New Antibiotics Unit in Himachal Pradesh........40

Biocat to Expand Presence in the Indian Market........40

PRWT Acquires Cherokee Chemical Unit from Merck........40

$100

CSPC Joins Hands with Indonesian Firms........41

$100

9. STRATEGIC CORPORATE DEVELOPMENTS IN THE RECENT PAST – A PERSPECTIVE BUILDER........42

$395

Nisshin-Kyorin to Merge with Kyorin Pharmaceutical........42

Schering-Plough Acquires Organon BioSciences........42

GSK & Anacor Partner for Boron Chemistry-Based Antibiotics and Antivirals........42

$100

Iroko Bags Canadian Rights to Vancocin®........43

Cubist Licenses CUBICIN Rights to Merck........43

Sagent Partners with Astral to Develop Injectable Antibiotics........43

MR Healthcare to Manufacture New Antibiotics & Medicines........43

$100

Livzon Synthetic to Acquire Antibiotic Intermediate from Jiaozuo........44

C&O Pharmaceutical to Distribute Meiact in China........44

Bioton Signs Deal to Market Antibiotics in Russia........44

Toyama Gains Marketing Approval for Geninax® in Japan........44

Forest Laboratories Acquires Cerexa........44

Oscient Modifies Licensing Agreement With LG Life Sciences........44

$100

Orchid Sign Licensing & Distribution Pact With Actavis........45

Forest Laboratories Revokes Partnership With Replidyne........45

SRI and Blanca Collaborate To Develop & Test Carbacephem........45

AstraZeneca To Expand Research Center For Antibiotics........45

Jade Pharmaceutical Begins Levofloxacin’s Production in China........45

$100

Reyoung To Start Antibiotic Production At New Facility........46

Toyama Begins T-705 Clinical Trials........46

SmPC For Sanofi-Aventis’ Ketek® Updated........46

Lupin Receives Approval for Cefpodoxime Proxetil Antiobiotic Tablets in France........46

Antibiotice Plans To Infuse Funds For Antibiotics Production........46

UAE Approves Pfizer’s Zithromax SD........46

$100

10. PRODUCT INNOVATIONS/INTRODUCTIONS........47

Janssen-Cilag Launches Doribax™ - New Carbapenem Antibiotic........47

MIT Scientists Develop a New Antibiotic, Rhodostreptomycin........47

Watson Pharma Introduces Biaxin XL’s Generic Version........47

$100

11. PRODUCT INNOVATIONS IN THE RECENT PAST – A PERSPECTIVE BUILDER........48

$295

Toyama Launches New Garenoxacin Quinolone Antibiotic........48

Wockhardt to Introduce Cefprozil in the US........48

MSD India Launches Invanza in India........48

Orchid Chemicals to Introduce Three New Drugs in the US........48

$100

DUSA Pharmaceuticals Releases ClindaReach™........49

Mylan Releases Cipro’s Generic Version........49

Macrolide Antibiotic Developed In the US........49

University of Michigan Devises NMR Spectroscopy For Antibiotics........49

Glycopeptide-Cephalosporin Antibiotics Developed In The US........49

Neosil Tests NEO 101 Antibiotic........49

New Antibiotic Developed By Canadian Inventors........49

$100

Abbott Canada Releases FACTIVE® Antibiotic Tablets In Canada........50

Penicillin Binding Protein Found In Japan........50

Venus Remedies Releases Mucomelt-Forte........50

$100

12. FOCUS ON SELECT GLOBAL PLAYERS........51

$950

Abbott Laboratories (USA)........51

Astellas Pharma, Inc. (Japan)........51

Bayer HealthCare AG (Germany)........51

$100

Bristol-Myers Squibb Co. (USA)........52

Cubist Pharmaceuticals, Inc. (USA)........52

$100

Daiichi Sankyo Company, Limited (Japan)........53

$100

Eli Lilly and Co. (USA)........54

GlaxoSmithKline Plc (UK)........54

$100

Johnson & Johnson (USA)........55

Kyorin Pharmaceutical Co., Ltd. (Japan)........55

$100

LG Life Sciences Limited (Korea)........56

$100

MiddleBrook™ Pharmaceuticals, Inc. (USA)........57

Novartis AG (Switzerland)........57

$100

Pfizer Inc. (USA)........58

$100

Pliva d.d. (Croatia)........59

Roche (Switzerland)........59

Sanofi-Aventis SA (France)........59

$100

Takeda Pharmaceutical Company, Ltd. (Japan)........60

Toyama Chemical Co., Ltd. (Japan)........60

$100

13. GLOBAL MARKET PERSPECTIVE........61

Table 9: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........61

$350

Table 10: World Historic Review for Antibiotics by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........62

$350

Table 11: World 11-Year Perspective for Antibiotics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)........63

$350

Table 12: World Recent Past, Current & Future Analysis for Penicillin by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........64

$350

Table 13: World Historic Review for Penicillin by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........65

$350

Table 14: World 11-Year Perspective for Penicillin by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)........66

$350

Table 15: World Recent Past, Current & Future Analysis for Cephalosporin by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........67

$350

Table 16: World Historic Review for Cephalosporin by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........68

$350

Table 17: World 11-Year Perspective for Cephalosporin by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)........69

$350

Table 18: World Recent Past, Current & Future Analysis for Macrolides by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........70

$350

Table 19: World Historic Review for Macrolides by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........71

$350

Table 20: World 11-Year Perspective for Macrolides by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)........72

$350

Table 21: World Recent Past, Current & Future Analysis for Quinolones by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........73

$350

Table 22: World Historic Review for Quinolones by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........74

$350

Table 23: World 11-Year Perspective for Quinolones by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)........75

$350

Table 24: World Recent Past, Current & Future Analysis for Carbapenems by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........76

$350

Table 25: World Historic Review for Carbapenems by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........77

$350

Table 26: World 11-Year Perspective for Carbapenems by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)........78

$350

Table 27: World Recent Past, Current & Future Analysis for Other Antibiotics by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........79

$350

Table 28: World Historic Review for Other Antibiotics by Geographic Region – US, Canada, Jap an, Europe, Asia- Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........80

$350

Table 29: World 11-Year Perspective for Other Antibiotics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)........81

$350

14. THE UNITED STATES........82

$950

A. Market Analysis........82

Current and Future Analysis........82

Antibiotics Approved Between 2000 and 2005 in the United States........82

$100

Competition........83

Table 30: Leading Players in the US Antibiotics Market (2008): Percentage Breakdown by Value Sales for Pfizer, Johnson & Johnson, GlaxoSmithKline, Abbott, and Others (includes corresponding Graph/Chart)........83

Key Players........83

$350

B. Market Analytics........84

Table 31: US Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........84

$350

Table 32: US Historic Review for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics MarketsIndependently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........85

$350

Table 33: US 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........86

$350

15. CANADA........87

$950

A. Market Analysis........87

Current And Future Analysis........87

B. Market Analytics........87

Table 34: Canadian Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........87

$350

Table 35: Canadian Historic Review for Antibiotics by Product Segment – Penicillin,Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........88

$350

Table 36: Canadian 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........89

$350

16. JAPAN........90

$950

A. Market Analysis........90

Current and Future Analysis........90

Key Players........90

$100

B. Market Analytics........91

Table 37: Japanese Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........91

$350

Table 38: Japanese Historic Review for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........92

$350

Table 39: Japanese 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........93

$350

17. EUROPE........94

$1950

A. Market Analysis........94

Current and Future Analysis........94

$100

B. Market Analytics........95

Table 40: European Recent Past, Current & Future Analysis for Antibiotics by Geographic Region – France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........95

$350

Table 41: European Historic Review for Antibiotics by Geographic Region – France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........96

$350

Table 42: European Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems, and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........97

$350

Table 43: European Historic Review for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems, and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........98

$350

Table 44: European 11-Year Perspective for Antibiotics by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........99

$350

Table 45: European 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems, and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........100

$350

17a. FRANCE........101

$950

A. Market Analysis........101

Current and Future Analysis........101

Trends........101

Over Consumption of Antibiotics – Cause of Concern........101

Sanofi-Aventis SA – A Key Player........101

$100

B. Market Analytics........102

Table 46: French Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........102

$350

Table 47: French Historic Review for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........103

$350

Table 48: French 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for2005, 2010 & 2015 (includes corresponding Graph/Chart)........104

$350

17b. GERMANY........105

$950

A. Market Analysis........105

Current and Future Analysis........105

Bayer HealthCare AG – A Key Player........105

$100

B. Market Analytics........106

Table 49: German Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........106

$350

Table 50: German Historic Review for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........107

$350

Table 51: German 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........108

$350

17c. ITALY........109

$950

A. Market Analysis........109

Current and Future Analysis........109

B. Market Analytics........109

Table 52: Italian Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........109

$350

Table 53: Italian Historic Review for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........110

$350

Table 54: Italian 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........111

$350

17d. THE UNITED KINGDOM........112

$950

A. Market Analysis........112

Current And Future Analysis........112

GlaxoSmithKline Plc – A Key Player........112

$100

B. Market Analytics........113

Table 55: UK Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........113

$350

Table 56: UK Historic Review for Antibiotics by Product Segment – Penicillin, Cephalosporin, acrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........114

$350

Table 57: UK 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for2005, 2010 & 2015 (includes corresponding Graph/Chart)........115

$350

17e. SPAIN........116

$950

Market Analysis........116

Table 58: Spanish Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........116

$350

Table 59: Spanish Historic Review for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........117

$350

Table 60: Spanish 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........118

$350

17f. REST OF EUROPE........119

$950

A. Market Analysis........119

Current and Future Analysis........119

Poland........119

Table 61: Polish Market for Antibiotics (2008): Percentage Breakdown of Market Share by Leading Companies – GSK Pharma, Bioton, Sandoz Corp, Ranbaxy and Others (includes corresponding Graph/Chart)........119

Focus On Select Players........119

$350

B. Market Analytics........120

Table 62: Rest of Europe Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........120

$350

Table 63: Rest of Europe Historic Review for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........121

$350

Table 64: Rest of Europe 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........122

$350

18. ASIA-PACIFIC........123

$950

A. Market Analysis........123

Current and Future Analysis........123

India........123

Rising Prices of Penicillin G to Affect Antibiotics Production........123

Market for Injectable Antibiotics Poised to Grow........123

$100

Cipla, Pharmaceutical Market Leader in 2009........124

China........124

Carbapenem Witnesses Robust Growth in China........124

$100

Key Players........125

Ranbaxy Laboratories Ltd. (India)........125

$100

B. Market Analytics........126

Table 65: Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........126

$350

Table 66: Asia-Pacific Historic Review for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........127

$350

Table 67: Asia-Pacific 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........128

$350

19. REST OF WORLD........129

$950

A. Market Analysis........129

Current and Future Analysis........129

$100

B. Market Analytics........130

Table 68: Rest of World Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)........130

$350

Table 69: Rest of World Historic Review for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)........131

$350

Table 70: Rest of World 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........132

$350

COMPETITION

708

$995

Total Companies Profiled: 197 (including Divisions/Subsidiaries - 238)
Region/Country                 Players

The United States                  48  
Canada                              8
Japan                              11
Europe                             66
     France                         7
     Germany                       10
     The United Kingdom             8
     Italy                         10
     Spain                          4
     Rest of Europe                27
Asia-Pacific (Excluding Japan)     87
Middle East                        13
Latin America                       4
Africa                              1

Click here to request a full table of contents and more details on this project.

ANTIBIOTICS - A GLOBAL STRATEGIC BUSINESS REPORT

Research Abstract

Complimentary Report Insights:

TABLE OF CONTENTS

ANTIBIOTICS - A GLOBAL STRATEGIC BUSINESS REPORT stLight.options({ publisher:'12345' });

Research Abstract

Complimentary Report Insights:

TABLE OF CONTENTS

ANTIBIOTICS - A GLOBAL STRATEGIC BUSINESS REPORT